<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sohn SH</submitter><funding>National Evidence-based Healthcare Collaborating Agency</funding><pagination>536-546</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11538586</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>57(6)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>This study compared the costs associated with transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in Korea by utilizing the National Health Insurance Service database.&lt;h4>Methods&lt;/h4>Between June 2015 and May 2019, 1,468 patients underwent primary isolated transfemoral TAVI, while 2,835 patients received primary isolated SAVR with a bioprosthesis. We assessed the costs of index hospitalization and subsequent healthcare utilization, categorizing the cohort into 6 age subgroups: &lt;70, 70-74, 75-79, 80-84, 85-89, and ≥90 years. The median follow-up periods were 2.5 and 3.0 years in the TAVI and SAVR groups, respectively.&lt;h4>Results&lt;/h4>The index hospitalization costs were 41.0 million Korean won (KRW) (interquartile range [IQR], 39.1-4</pubmed_abstract><journal>Journal of chest surgery</journal><pubmed_title>Costs Associated with Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement in Korea.</pubmed_title><pmcid>PMC11538586</pmcid><funding_grant_id>HC21C0180010021</funding_grant_id><pubmed_authors>Lim C</pubmed_authors><pubmed_authors>Shinn SH</pubmed_authors><pubmed_authors>Lee SH</pubmed_authors><pubmed_authors>Sohn SH</pubmed_authors><pubmed_authors>Kim KH</pubmed_authors><pubmed_authors>Choi JW</pubmed_authors><pubmed_authors>Kang Y</pubmed_authors><pubmed_authors>Yoo JS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Costs Associated with Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement in Korea.</name><description>&lt;h4>Background&lt;/h4>This study compared the costs associated with transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in Korea by utilizing the National Health Insurance Service database.&lt;h4>Methods&lt;/h4>Between June 2015 and May 2019, 1,468 patients underwent primary isolated transfemoral TAVI, while 2,835 patients received primary isolated SAVR with a bioprosthesis. We assessed the costs of index hospitalization and subsequent healthcare utilization, categorizing the cohort into 6 age subgroups: &lt;70, 70-74, 75-79, 80-84, 85-89, and ≥90 years. The median follow-up periods were 2.5 and 3.0 years in the TAVI and SAVR groups, respectively.&lt;h4>Results&lt;/h4>The index hospitalization costs were 41.0 million Korean won (KRW) (interquartile range [IQR], 39.1-4</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Nov</publication><modification>2026-07-16T13:08:39.031Z</modification><creation>2025-04-04T03:04:30.557Z</creation></dates><accession>S-EPMC11538586</accession><cross_references><pubmed>39434612</pubmed><doi>10.5090/jcs.24.048</doi></cross_references></HashMap>